Compare Stocks

Date Range: 

 Rexahn PharmaceuticalsTower One WirelessSciSparcAcerus PharmaceuticalsGlobeImmune
SymbolNASDAQ:REXNOTCMKTS:TOWTFOTCMKTS:SPRCYOTCMKTS:TRLPFOTCMKTS:GBIM
Price Information
Current PriceN/A$0.09$5.25$0.04$0.40
50-Day Moving Average$2.06$0.09$7.28$0.04$0.95
52-Week Low$1.26$0.03$2.75$0.08$0.10
52-Week High$4.26$0.14$12.25$0.34$5.46
MarketRank™
Overall Score0.90.01.30.91.2
Analysis Score0.00.00.00.00.0
Community Score4.30.05.04.44.1
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.01.7
Earnings & Valuation Score0.00.01.30.00.0
Analyst Ratings
Consensus RecommendationN/AN/ABuyN/AN/A
Consensus Price TargetN/AN/A$20.00N/AN/A
% Upside from Price TargetN/AN/A280.95% upsideN/AN/A
Trade Information
Market Cap$8.11 million$8.30 million$5.44 million$9.05 million$2.31 million
Beta0.980.13-0.082.521.95
Average Volume162,96889,10610,0395,47430,379
Sales & Book Value
Annual RevenueN/A$6.81 millionN/A$7.38 millionN/A
Price / SalesN/A1.22N/A1.23N/A
CashflowN/AN/A$3.60 per shareN/AN/A
Price / CashN/AN/A1.46N/AN/A
Book Value$2.48 per share($0.09) per share$1.38 per shareN/AN/A
Price / BookN/A-0.98N/A∞N/A
Profitability
Net Income$-8,640,000.00$-1,760,000.00$-3,480,000.00$-18,790,000.00N/A
EPSN/AN/A$14.94N/AN/A
Trailing P/E Ratio0.00N/A0.350.000.00
Forward P/E RatioN/A∞N/A∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-43.79%N/A-254.66%N/A
Return on Equity (ROE)-72.60%N/AN/A-346.72%N/A
Return on Assets (ROA)-55.68%-27.19%N/A-94.54%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.64%N/A
Current Ratio3.37%0.11%2.25%1.35%N/A
Quick Ratio3.37%0.11%2.25%0.90%N/A
Ownership Information
Institutional Ownership Percentage7.49%N/AN/A0.02%N/A
Insider Ownership Percentage1.10%N/AN/AN/A23.50%
Miscellaneous
Employees5N/A2293
Shares Outstanding4.48 million94.10 million1.04 million258.62 million5.75 million
Next Earnings DateN/A8/30/2021 (Estimated)N/AN/AN/A
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
GlobeImmune (OTCMKTS:GBIM) Share Price Crosses Below Fifty Day Moving Average of $1.03GlobeImmune (OTCMKTS:GBIM) Share Price Crosses Below Fifty Day Moving Average of $1.03
americanbankingnews.com - July 27 at 3:10 AM
GlobeImmune Announces Third Quarter 2015 Results and Corporate HighlightsGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
www.bloomberg.com - March 4 at 8:15 PM
GlobeImmune Announces Second Quarter 2015 Results and Corporate HighlightsGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
www.bloomberg.com - February 20 at 11:07 PM
GlobeImmune Inc.GlobeImmune Inc.
www.barrons.com - October 24 at 10:26 PM
DateCompanyBrokerageAction
2/16/2021SciSparcAegis
Reiterated Rating
8/7/2019Rexahn PharmaceuticalsIfs Securities
Downgrade
8/7/2019Rexahn PharmaceuticalsHC Wainwright
Downgrade
4/17/2019Rexahn PharmaceuticalsHC Wainwright
Set Price Target
3/8/2019Rexahn PharmaceuticalsHC Wainwright
Reiterated Rating
2/5/2019Rexahn PharmaceuticalsHC Wainwright
Lower Price Target
1/15/2019Rexahn PharmaceuticalsHC Wainwright
Reiterated Rating
12/6/2018Rexahn PharmaceuticalsHC Wainwright
Set Price Target
11/27/2018Rexahn PharmaceuticalsBrookline Capital Management
Reiterated Rating
11/5/2018Rexahn PharmaceuticalsHC Wainwright
Set Price Target
10/4/2018Rexahn PharmaceuticalsIfs Securities
Upgrade
10/2/2018Rexahn PharmaceuticalsB. Riley
Set Price Target
10/2/2018Rexahn PharmaceuticalsHC Wainwright
Set Price Target
9/25/2018Rexahn PharmaceuticalsHC Wainwright
Set Price Target
8/13/2018Rexahn PharmaceuticalsB. Riley
Set Price Target
8/6/2018Rexahn PharmaceuticalsHC Wainwright
Set Price Target
(Data available from 8/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.